Beta-Lactamase DataBase (BLDB): Structure and Function
Beta-Lactamase DataBase
Beta-Lactamase DataBase - Structure and Function Home Enzymes Structures Mutants Kinetics BLAST
Beta-Lactamase DataBase

Sequence alignment for the XCC beta-lactamase family

XCC-1
........10........20........30........40........50........60........70........80........90.......100.......110.......120.......130.......140.......150.......160.......170.......180.......190.......200.......210.......220.......230.......240.......250.......260.......270.......280.......290......
MLNRRQFLSMTGASVLIAASRPAWALSPVVNVDDMLRARWAEIQRGTGGRLGTCLLDSGSGWRIGQRENERFPMCSTFKFVLAAAVLQRVDKGELRLTQQIKIRASDMLEHAPVTERHVGGSLSVAELCQATMIHSDNPAANLLFPLIGDPPGLTRFLRGIGDTKTRSDRLE-AMNGFAPGEPRDTTTPAAMAATLRTLLLGDALQPASRKQLTAWMIDNRTGDDCLRAGLPRDWKIGDKTGSNGTDTRNDIAIIWPPGRAAPLLLTAYLNGATVDAAARDAALKAVAEAVRDLVG
XCC-2............................................................................................................................................................................P........................................................................................................................... 99.66 %
XCC-3....................K.SQ.V.L.ASPIAE..YK.......S.....IS..N.DT..H......................................................................................N......................PE...............................R........................................................................G................. 91.55 %
XCC-4....................K.SQ.V.L.ASPIAE..YK.......S.....IS..N.DT..H......................................................................................N......................PE........................................................................................................G.........A....... 91.55 %
XCC-5....................K.SQ.V.L.ASPIAE..YK.......S.....IS..N.DT..H......................................................................................N......................PE....................................Q...................................................................G................. 91.55 %
XCC-6....................K.SQ.V.L.ASPIAE..YK.......S.....IS..N.DT..H......................................................................................N......................PE....................................................................................................I...G................. 91.55 %
XCC-7....................K.SQ.V.L.ASPIAE..YK.......S.....IS..N.DT..H......................................................................................N.....L................PE..................................................G.....................................................G................. 91.22 %
XCC-8......................SQ.V.L.ASPIAE..YK....E..S.....IG..N.DT..H....................................................................................V........................PE........................................................................................................G.........A....... 91.55 %
XCC-9............................................................................................................................................................................P................................H.......................................................................................... 99.32 %
XCC-10......................SQ.V.L.ASPIAE..YK....E..S.....IG..N.DT..H.............................................................................................................PE...........................................................................................................V.............. 92.23 %
XCC-11......L.....................................................................................................................................................................P........................................................................................................................... 99.32 %
XCC-12..........A.................A..EY.V.................IS..N.VT..H.................................................S....................................N.......M..............PE......................................................................................T.................G................. 93.92 %
XCC-13............................A..EY.V.................IS..N.VT..H..............................................................................................M..............PE...................................................................................................A.......V.............. 94.93 %
XCC-14............................A..EY.V.................IS..N.VT..H.............................................................................................................P...................................................................................L.....................G................. 95.61 %
XCC-15............................A..EY.V.................IS..N.VT..H......................................................................................N......................PE.......................................................................................................................... 95.61 %
XCC-16.....................................................................................................................................................N......................PE...............V......................................................................T.................G................. 97.97 %
XCC-17........................T............................................................................................................................N......................PE.........C............................................................................T.................G................. 97.64 %
XCC-18.....................................................................................................................................................N......................PE.........C............................................................................T.................G................. 97.97 %
XCC-19................................................................................I................M...................................................N......................PE........................................................................................................G................. 97.97 %
XCC-20............................A....................................................................M...................................................N......................PQ........................................................................................................G................. 97.97 %
XCC-21............................A..............................T..H...........................................................................................................I.PE.......................................A................................................................G................. 97.30 %
XCC-22........................................................................................Q.................................................................................I.PE........................................................................................................G................. 98.31 %
XCC-23............................A...............................................................................................................................................PE..................................................................................................................A....... 98.65 %
A-XCC phylogenetic tree

Last updated: December 22, 2025.

If you use BLDB please cite: Naas, T.; Oueslati, S.; Bonnin, R. A.; Dabos, M. L.; Zavala, A.; Dortet, L.; Retailleau, P.; Iorga, B. I., Beta-Lactamase DataBase (BLDB) – Structure and Function. J. Enzyme Inhib. Med. Chem. 2017, 32, 917-919.

The development of the BLDB database was funded in part by the JPIAMR transnational project DesInMBL, the Région Ile-de-France (DIM Malinf) and the Laboratory of Excellence in Research on Medication and Innovative Therapeutics (LERMIT).

Contact: contact@bldb.eu

Live statistics (since March 29th, 2025)